Cisplatin combined with capecitabine-induced chemotherapy for local nasopharyngeal carcinoma can improve the quality of life and reduce toxic and side effects

Gao, Ying; Zhe, Liu; Liu, Yiting

doi:10.1186/s12957-021-02393-1

Cited by 2 publications

(2 citation statements)

References 33 publications

(32 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another oral fluoropyrimidine cytotoxic drug called capecitabine was also assessed for its efficacy as adjuvant by combining with cisplatin compared to the efficacy when cisplatin was used alone [ 413 ]. Chemo- and radiotherapy-naïve patients aged ≥ 18 years old with locally advanced (stage III–IVa) NPC, and no other tumor were enrolled.…”

Section: Recent Clinical Advancement Of Precision Medicine In Npcmentioning

confidence: 99%

Precision medicine in nasopharyngeal carcinoma: comprehensive review of past, present, and future prospect

Siak,

Heng,

Teoh

et al. 2023

J Transl Med

View full text Add to dashboard Cite

Nasopharyngeal carcinoma (NPC) is an aggressive malignancy with high propensity for lymphatic spread and distant metastasis. It is prominent as an endemic malignancy in Southern China and Southeast Asia regions. Studies on NPC pathogenesis mechanism in the past decades such as through Epstein Barr Virus (EBV) infection and oncogenic molecular aberrations have explored several potential targets for therapy and diagnosis. The EBV infection introduces oncoviral proteins that consequently hyperactivate many promitotic pathways and block cell-death inducers. EBV infection is so prevalent in NPC patients such that EBV serological tests were used to diagnose and screen NPC patients. On the other hand, as the downstream effectors of oncogenic mechanisms, the promitotic pathways can potentially be exploited therapeutically. With the apparent heterogeneity and distinct molecular aberrations of NPC tumor, the focus has turned into a more personalized treatment in NPC. Herein in this comprehensive review, we depict the current status of screening, diagnosis, treatment, and prevention in NPC. Subsequently, based on the limitations on those aspects, we look at their potential improvements in moving towards the path of precision medicine. The importance of recent advances on the key molecular aberration involved in pathogenesis of NPC for precision medicine progression has also been reported in the present review. Besides, the challenge and future outlook of NPC management will also be highlighted.

show abstract

Section: Recent Clinical Advancement Of Precision Medicine In Npcmentioning

confidence: 99%

Precision medicine in nasopharyngeal carcinoma: comprehensive review of past, present, and future prospect

Siak,

Heng,

Teoh

et al. 2023

J Transl Med

View full text Add to dashboard Cite

show abstract

“…The study designed by Gao et al investigated the benefit of reducing the toxicity profile for a combined cisplatin–capecitabine induction regimen in NPCs. Data analysis in a group of 136 patients demonstrated the ability of the cisplatin–capecitabine combination regimen delivered in induction settings to reduce HNSCC therapy-associated toxicities [ 28 , 29 , 30 , 31 ].…”

Section: Capecitabine In Induction Chemotherapymentioning

confidence: 99%

Capecitabine—A “Permanent Mission” in Head and Neck Cancers “War Council”?

Mireștean

Iancu

2022

JCM

View full text Add to dashboard Cite

Capecitabine, an oral pro-drug that is metabolized to 5-FU, has been used in clinical practice for more than 20 years, being part of the therapeutic standard for digestive and breast cancers. The use of capecitabine has been evaluated in many trials including cases diagnosed in recurrent or metastatic settings. Induction regimens or a combination with radiation therapy were evaluated in head and neck cancers, but 5-FU still remained the fluoropyrimidine used as a part of the current therapeutic standard. Quantifications of levels or ratios for enzymes are involved in the capecitabine metabolism to 5-FU but are also involved in its conversion and elimination that may lead to discontinuation, dose reduction or escalation of treatment in order to obtain the best therapeutic ratio. These strategies based on biomarkers may be relevant in the context of the implementation of precision oncology. In particular for head and neck cancers, the identification of biomarkers to select possible cases of severe toxicity requiring discontinuation of treatment, including “multi-omics” approaches, evaluate not only serological biomarkers, but also miRNAs, imaging and radiomics which will ensure capecitabine a role in both induction and concomitant or even adjuvant and palliative settings. An approach including routine testing of dihydropyrimidine dehydrogenase (DPD) or even the thymidine phosphorylase (TP)/DPD ratio and the inclusion of miRNAs, imaging and radiomics parameters in multi-omics models will help implement “precision chemotherapy” in HNC, a concept supported by the importance of avoiding interruptions or treatment delays in this type of cancer. The chemosensitivity and prognostic features of HPV-OPC cancers open new horizons for the use of capecitabine in heavily pretreated metastatic cases. Vorinostat and lapatinib are agents that can be associated with capecitabine in future clinical trials to increase the therapeutic ratio.

show abstract

Cisplatin combined with capecitabine-induced chemotherapy for local nasopharyngeal carcinoma can improve the quality of life and reduce toxic and side effects

Cited by 2 publications

References 33 publications

Precision medicine in nasopharyngeal carcinoma: comprehensive review of past, present, and future prospect

Precision medicine in nasopharyngeal carcinoma: comprehensive review of past, present, and future prospect

Capecitabine—A “Permanent Mission” in Head and Neck Cancers “War Council”?

Contact Info

Product

Resources

About